Renaud Bussiere

Dr. Renaud Bussiere

Neuro-Sys, Gardanne, Provence-Alpes-Côte d’Azur, France
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
ALAlain Lacampagne
Alain Lacampagne
XLXiaoping Liu
Xiaoping Liu
SRSteven Reiken
Steven Reiken
RBRenaud Bussiere
Renaud Bussiere
AMAlbano Meli
Albano Meli
AMAndrew R. Marks
Andrew R. Marks

20 December 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
DPDolores Del Prete
Dolores Del Prete
JSJan M. Suski
Jan M. Suski
BOBénédicte Oulès
Bénédicte Oulès
DDDelphine Debayle
Delphine Debayle
AGAnne Sophie Gay
Anne Sophie Gay
Mounia ChamiMounia Chami
Mounia Chami
Alteration of mitochondria-associated membranes (MAMs) has been proposed to contribute to the pathogenesis of Alzheimer's disease (AD). We studied herein the subcellular distribution, the processing, and the protein interactome of the amyloid-β protein precursor (AβPP) and its proteolytic products in MAMs. We reveal that AβPP and its catabolites are present in MAMs in cellular models overexpressing wild type AβPP or AβPP harboring the double Swedish or London familial AD mutations, and in brains of transgenic mice model of AD. Furthermore, we evidenced that both β- and γ-secretases are present and harbor AβPP processing activities in MAMs. Interestingly, cells overexpressing APPswe show increased ER-mitochondria contact sites. We also document increased neutral lipid accumulation linked to Aβ production and reversed by inhibiting β- or γ-secretases. Using a proteomic approach, we show that AβPP and its catabolites interact with key proteins of MAMs controlling mitochondria and ER functions. These data highlight the role of AβPP processing and proteomic interactome in MAMs deregulation taking place in AD.

1 June 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RBRenaud Bussiere
Renaud Bussiere
ALAlain Lacampagne
Alain Lacampagne
SRSteven Reiken
Steven Reiken
XLXiaoping Liu
Xiaoping Liu
VSValerie Scheuerman
Valerie Scheuerman
Mounia ChamiMounia Chami
Mounia Chami
Alteration of ryanodine receptor (RyR)-mediated calcium (Ca2+) signaling has been reported in Alzheimer disease (AD) models. However, the molecular mechanisms underlying altered RyR-mediated intracellular Ca2+ release in AD remain to be fully elucidated. We report here that RyR2 undergoes post-translational modifications (phosphorylation, oxidation, and nitrosylation) in SH-SY5Y neuroblastoma cells expressing the β-amyloid precursor protein (βAPP) harboring the familial double Swedish mutations (APPswe). RyR2 macromolecular complex remodeling, characterized by depletion of the regulatory protein calstabin2, resulted in increased cytosolic Ca2+ levels and mitochondrial oxidative stress. We also report a functional interplay between amyloid β (Aβ), β-adrenergic signaling, and altered Ca2+ signaling via leaky RyR2 channels. Thus, post-translational modifications of RyR occur downstream of Aβ through a β2-adrenergic signaling cascade that activates PKA. RyR2 remodeling in turn enhances βAPP processing. Importantly, pharmacological stabilization of the binding of calstabin2 to RyR2 channels, which prevents Ca2+ leakage, or blocking the β2-adrenergic signaling cascade reduced βAPP processing and the production of Aβ in APPswe-expressing SH-SY5Y cells. We conclude that targeting RyR-mediated Ca2+ leakage may be a therapeutic approach to treat AD.

28 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
RBRenaud Bussiere
Renaud Bussiere
BOBénédicte Oulès
Bénédicte Oulès
AMArnaud Mary
Arnaud Mary
LVLoan Vaillant-Beuchot
Loan Vaillant-Beuchot
CMCécile Martin
Cécile Martin
Mounia ChamiMounia Chami
Mounia Chami
Dysregulation of the Endoplasmic Reticulum (ER) Ca2+ homeostasis and subsequent ER stress activation occur in Alzheimer Disease (AD). We studied the contribution of the human truncated isoform of the sarco-endoplasmic reticulum Ca2+ ATPase 1 (S1T) to AD. We examined S1T expression in human AD-affected brains and its functional consequences in cellular and transgenic mice AD models. S1T expression is increased in sporadic AD brains and correlates with amyloid β (Aβ) and ER stress chaperone protein levels. Increased S1T expression was also observed in human neuroblastoma cells expressing Swedish-mutated β-amyloid precursor protein (βAPP) or treated with Aβ oligomers. Lentiviral overexpression of S1T enhances in return the production of APP C-terminal fragments and Aβ through specific increases of β-secretase expression and activity, and triggers neuroinflammation. We describe a molecular interplay between S1T-dependent ER Ca2+ leak, ER stress and βAPP-derived fragments that could contribute to AD setting and/or progression.

21 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RBRenaud Bussiere
Renaud Bussiere
NTNikhil Tulsian
Nikhil Tulsian
CWCecilia Wieder
Cecilia Wieder
DMDewi McConnaughie
Dewi McConnaughie
ETEvie Tynan
Evie Tynan
SGSébastien Gillotin
Sébastien Gillotin
Excessive iron accumulation is a pathological feature of several neurodegenerative diseases (NDDs) and a growing body of evidence suggests that ferroptosis, an iron-dependent form of regulated cell death (RCD) driven by lipid peroxidation, is implicated in their pathogenesis. Microglia, the brain’s resident immune cells, buffer iron overload but become susceptible to ferroptotic death, exacerbating neuroinflammation and neuronal loss. To uncover the molecular events leading to microglial ferroptosis, we established a human microglial ferroptosis model using the HMC3 cell line. This model recapitulates core features of ferroptosis, including increased reactive oxygen species (ROS) and peroxidation of lipids at the membrane, both rescued by Ferrostatin-1 (Fer-1). We used this model to perform integrated multi-omics profiling and identified significant dysregulation in lipid species, notably an accumulation of sterols, including oxysterols such as the 7-oxo-cholesterol, alongside the oxidation of polyunsaturated fatty acid (PUFA) characteristic of ferroptosis. Transcriptomic and proteomic analyses corroborated these findings, revealing the upregulation of genes and proteins involved in the mevalonate pathway and cholesterol metabolism. Importantly, the increased expression of some of these key metabolic genes was also reversed by Fer-1 treatment, indicating their role in a pre-ferroptotic signature. Our model provides a novel platform for investigating early molecular events in microglia ferroptosis. Integrating these findings into future investigations could uncover new protective mechanisms against microglia ferroptosis at the crossroad between ROS level mitigation and sterol metabolism.

3 April 2026
Verified
Thesis
Closed access
RBRenaud Bussiere
Renaud Bussiere
Le calcium (Ca2+) joue un rôle prépondérant dans la fonction de nos neurones et du système nerveux central. Différents travaux ont rapporté que la dérégulation de l’homéostasie calcique, est associée au développement de la Maladie d’Alzheimer (MA). Durant ma thèse, j’ai étudié l’implication de deux acteurs importants de l’homéostasie calcique du Réticulum Endoplasmique (RE) : 1) le Récepteur de la Ryanodine (RyR) faisant sortir le Ca2+ vers le cytosol et 2) l’isoforme tronquée de la Sarco-Endoplasmic Reticulum Ca2+ ATPase 1 (S1T), ayant perdu la fonction de pompe calcique et jouant un rôle dans la fuite passive du Ca2+ du RE. Au cours de ma thèse j’ai démontré le mécanisme moléculaire impliqué dans la dérégulation de l’activité de l’isoforme RyR2 dans des modèles d’étude in vitro et in vivo de la MA. Nous avons montré que le RyR2 subit des modifications post-traductionnelles (MPTs) (phosphorylation, oxydation, nitrosylation) dans le cerveau de patients atteints de la MA et dans des modèles murins de la maladie. Nous avons identifié une cascade dans laquelle l’Amyloïde β (Aβ) active les récepteurs β2-Adrénergiques, conduisant aux MPTs du RyR2 aboutissant à la dissociation de la protéine régulatrice Calstabine2 du macrocomplexe du RyR2 et à l’augmentation de la fuite de Ca2+ du RE. Nous avons aussi mis en évidence la possibilité de réduire les MPTs du RyR2 et de stabiliser la Calstabine2 sur le macrocomplexe RyR2 en inhibant pharmacologiquement la cascade β2-Adrénergique. Par ailleurs, nous avons également stabilisé la Calstabine2 par des moyens pharmacologiques (in vitro et in vivo) ou génétiques (in vivo). Nos résultats montrent que cela permet non seulement de limiter la fuite de Ca2+ mais également de réduire le métabolisme du Précurseur du Peptide Amyloïde (APP) et les dépôts d’Aβ in vitro et in vivo et le déficit cognitif et les défauts de plasticité synaptique dans deux modèles murins d’étude de la MA. Nos résultats ont également montré l’existence d’une boucle d’amplification de la pathologie dans laquelle la dérégulation calcique liée au RyR accroit la production de l’Aβ qui va en retour induire les modifications du RyR. Par ailleurs, je me suis également intéressé à l’implication potentielle de S1T dans la MA. Nos résultats révèlent : 1) l’expression de S1T dans les cerveaux de patients Alzheimer et dans un modèle in vitro de la MA ; 2) l’induction de S1T par l’Aβ, 3) l’impact de l’expression de S1T sur le métabolisme de l’APP et 4) l’impact de l’expression de S1T sur la neuroinflammation dans des modèles in vitro et in vivo. L’article issu de cette seconde étude est en cours de soumission. Ainsi l’augmentation de la fuite du Ca2+ du RE vers le cytosol semble être particulièrement impliquée dans la physiopathologie de la MA. Le canal RyR2 se révèlerait être un candidat intéressant à cibler pour des approches thérapeutiques visant à réguler son activité dans le but de prévenir ou guérir la MA.